Market Overview

Seattle, Genetics Takeda Highlight Long-term Follow-up Data from ADCETRIS Pivotal Clinical Trials at ASH


Genetics (Nasdaq: SGEN) and Takeda
Pharmaceutical Company Limited (OTC: TKPYY) today announced updated
overall survival data from two ADCETRIS (brentuximab vedotin) pivotal
Phase 2 clinical trials in relapsed/refractory Hodgkin lymphoma (R/R HL)
and relapsed/refractory systemic anaplastic large cell lymphoma (R/R
sALCL) were presented at the 55th American Society of
Hematology (ASH) Annual Meeting and Exposition taking place in New
Orleans, LA, December 7-10, 2013. ADCETRIS is an antibody-drug conjugate
(ADC) directed to CD30. Median overall survival (OS) of 40.5 months was
reported in R/R HL, and was not yet reached in R/R sALCL.

“The updated data from the pivotal ADCETRIS clinical trials demonstrate
extended survival among this heavily

See full press release

Posted-In: News Guidance Buybacks Management Global


Related Articles (SGEN + TKPYY)

View Comments and Join the Discussion!

ImmunoGen Announces Activity Reported with SAR3419 Plus Rituxan In Difficult-to-Treat Patient Population at ASH

Five Star Stock Watch: eBay, Inc.